Valius Sciences develops personalized cancer maps by analyzing DNA, RNA, and protein profiles to uncover specific tumor weaknesses. This comprehensive molecular insight guides the identification of the most effective targeted therapies for individual patients. The company translates these complex omics data into actionable treatment strategies for clinicians.
Funding
Funding not disclosed
Founders
Product
Problem
Identifying specific molecular vulnerabilities within heterogeneous cancer cell populations is a complex challenge. This complexity can lead to suboptimal therapeutic selection, impacting patient outcomes.
Solution
Valius Sciences provides comprehensive molecular profiling services to elucidate the unique biological landscape of a patient's cancer. Our platform leverages advanced genomic and proteomic analysis to pinpoint actionable targets and resistance mechanisms within tumor cells. We translate these complex molecular insights into clear, data-driven treatment recommendations for oncologists and their care teams. This approach facilitates informed decision-making, enabling the selection of more precise and effective therapeutic strategies.
Target Audience
Our primary customers are oncologists, cancer researchers, and academic medical centers seeking advanced molecular diagnostics to guide personalized cancer therapy.
Features
- Whole-exome and targeted gene sequencing for comprehensive genomic analysis.
- Proteomic profiling to identify protein expression levels and post-translational modifications.
- Bioinformatic pipeline for variant calling, pathway analysis, and identification of actionable mutations.
- Machine learning algorithms to predict drug sensitivity and resistance based on molecular profiles.
- Integrated reporting that correlates molecular findings with therapeutic options.
- Dedicated scientific liaison to collaborate with clinical teams on data interpretation.